Conclusions
To conclude, in this meta-regression, we found evidence to suggest that
the efficacy of eptinezumab, an anti-CGRP monoclonal antibody
administered by IV, is likely underestimated in ITCs that assume a
common placebo effect. The contextual placebo effects inherent in
current clinical trial design require further scrutiny, and alternative
comparison methods (other than standard Bayesian network meta-analysis)
may need to be implemented to ensure accurate and unbiased treatment
comparisons.